Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused millions of
deaths and substantial morbidity worldwide. Intense scientific effort to understand the …

SARS-CoV-2 is the causative agent of the COVID-19 pandemic. The approval of vaccines
and small-molecule antivirals is vital in combating the pandemic. The viral polymerase …

Nirmatrelvir, an oral antiviral targeting the 3CL protease of SARS-CoV-2, has been
demonstrated to be clinically useful against COVID-19 (refs.,). However, because SARS …

As of December 2022, there have been over 642 million confirmed cases of COVID-19 (10).
The pandemic has thus far claimed approximately 6.62 million lives (10). Vaccination is …

The nucleoside analog remdesivir (RDV) is a Food and Drug Administration–approved
antiviral for treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …

During the coronavirus disease 2019 (COVID-19) pandemic, a wave of rapid and
collaborative drug discovery efforts took place in academia and industry, culminating in …

Background and objectives To understand how organisms evolve, it is fundamental to study
how mutations emerge and establish. Here, we estimated the rate of mutation accumulation …

Persistent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections have
been reported in immune-compromised individuals and people undergoing immune …

Coronaviruses (CoVs) constitute a large and diverse subfamily of positive-sense single-
stranded RNA viruses. They are found in many mammals and birds and have great …

SARS-CoV-2 remdesivir resistance mutations have been generated in vitro but have not
been reported in patients receiving treatment with the antiviral agent. We present a case of …